Moreover, SPR inhibition in vivo resulted in reduced severity of T cell-mediated inflammation in models of colitis, allergic hypersensitivity and multiple sclerosis (Cronin et al., 2018; Schmitz et al., 2021), thus highlighting the potential of peripheral SPR inhibition in conditions where over-zealous T Cells are fighting against one’s own body. The gene discussed is SPR; the disease is colitis.